\ UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) June 30, 2003
--------------------------------
INTEGRATED BIOPHARMA, INC.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-28876 22-2407475
--------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
201 Route 22, Hillside, New Jersey 07205
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (973) 926-0816
--------------------------------------------
NOT APPLICABLE
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events and Required FD Disclosure.
On June 30, 2003, Integrated BioPharma, Inc., a Delaware corporation,
issued a press release regarding completion of a private placement. The press
release is included as Exhibit 99.1 to this Form 8-K and is incorporated herein
by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
Exhibit No. Description
----------- -----------
99.1 Press Release, dated June 30, 2003, entitled "Integrated
BioPharma Completes $9.5 Million Private Placement."
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
INTEGRATED BIOPHARMA, INC.
Date: July 10, 2003
By: /s/ Eric Friedman
----------------------
Name: Eric Friedman
Title: Chief Financial Officer